{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"institution":[{"name":"Research Square"}],"indexed":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T09:45:29Z","timestamp":1776764729767,"version":"3.51.2"},"posted":{"date-parts":[[2026,4,8]]},"group-title":"In Review","reference-count":31,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T00:00:00Z","timestamp":1775606400000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"accepted":{"date-parts":[[2026,3,25]]},"abstract":"<title>Abstract<\/title>\n                <p>Systemic light chain amyloidosis (AL) arises from monoclonal immunoglobulin light chains, but determinants of progression from precursor states remain poorly defined.\nIn a cross-sectional cohort comprising 1950 systemic AL patients diagnosed 2010-2024, 258 (13.2%) patients with a previously diagnosed plasma cell disorder (PCD) were compared to patients with no prior PCD diagnosis. Patients with monoclonal gammopathy of undetermined signficance (MGUS) and smoldering multiple myeloma (SMM) in the former group had lower difference between involved and uninvolved FLCs (dFLC), higher M-protein, and lower rates of t(11;14) at AL diagnosis. Patients developing AL from SMM had a shorter time to AL (median 34.2 versus 61.3 months) and higher dFLC (median 28.9 versus  11.0 mg\/dl) compared to those from MGUS. Patients developing AL after known multiple myeloma (MM) or lymphoplasmacytic lymphoma (LPL) commonly lacked deep hematologic response before AL (\u2264 very good partial response in 78% of MM, 100% of LPL patients).\nWe additionally studied longitudinally followed cohorts of 3,966 MGUS and 426 (SMM) patients with longitudinal FLC measurements and matched follow-up, in which 1.8% of MGUS and 7.2% of SMM patients developed AL. Those patients who developed AL showed markedly higher dFLC at MGUS\/SMM diagnosis and more frequent \u03bb restriction and rates of t(11;14). Higher dFLC was associated with progressively earlier AL development; a 10% cumulative risk occurred at 20 months for patients with a dFLC &gt;80 mg\/dL but was not reached if dFLC &lt;10 mg\/dL at an estimated median follow-up of 86 months. In multivariable analysis, dFLC &gt;6.4 mg\/dL (HR 11.3) and \u03bb isotype (HR 3.6) independently predicted AL, whereas heavy chain secretion was associated with lower risk (HR 0.2 for IgG).\nThese findings indicate that AL risk is primarily driven by cumulative light chain exposure, refining our knowledge of AL pathophysiology and providing guidance for follow-up of patients with elevated dFLC.<\/p>","DOI":"10.21203\/rs.3.rs-9227260\/v1","type":"posted-content","created":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T05:24:51Z","timestamp":1775625891000},"source":"Crossref","is-referenced-by-count":0,"title":["Risk of AL Amyloidosis is Associated with Degree of Free Light Chain Elevation and Duration of Exposure"],"prefix":"10.21203","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8780-9512","authenticated-orcid":false,"given":"Angela","family":"Dispenzieri","sequence":"first","affiliation":[{"name":"Mayo Clinic"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3644-9187","authenticated-orcid":false,"given":"Maximilian","family":"Steinhardt","sequence":"additional","affiliation":[{"name":"Mayo Clinic"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2210-2174","authenticated-orcid":false,"given":"Eli","family":"Muchtar","sequence":"additional","affiliation":[{"name":"Mayo Clinic"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8573-9434","authenticated-orcid":false,"given":"Taxiarchis","family":"Kourelis","sequence":"additional","affiliation":[{"name":"Mayo Clinic"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rahma","family":"Warsame","sequence":"additional","affiliation":[{"name":"Mayo Clinic"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3214-0203","authenticated-orcid":false,"given":"Francis","family":"Buadi","sequence":"additional","affiliation":[{"name":"Mayo Clinic"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7477-3004","authenticated-orcid":false,"given":"David","family":"Dingli","sequence":"additional","affiliation":[{"name":"Mayo Clinic"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5651-1411","authenticated-orcid":false,"given":"Nelson","family":"Leung","sequence":"additional","affiliation":[{"name":"Mayo Clinic"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5335-9533","authenticated-orcid":false,"given":"Joselle","family":"Cook","sequence":"additional","affiliation":[{"name":"Mayo Clinic"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8284-3495","authenticated-orcid":false,"given":"Ronald","family":"Go","sequence":"additional","affiliation":[{"name":"Mayo Clinic"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suzanne","family":"HAYMAN","sequence":"additional","affiliation":[{"name":"Mayo Clinic"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6890-969X","authenticated-orcid":false,"given":"Wilson","family":"Gonsalves","sequence":"additional","affiliation":[{"name":"Mayo Clinic"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4342-364X","authenticated-orcid":false,"given":"Prashant","family":"Kapoor","sequence":"additional","affiliation":[{"name":"Mayo Clinic"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5074-8453","authenticated-orcid":false,"given":"Saurabh","family":"Zanwar","sequence":"additional","affiliation":[{"name":"Mayo Clinic"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9014-9658","authenticated-orcid":false,"given":"Moritz","family":"Binder","sequence":"additional","affiliation":[{"name":"Mayo Clinic"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-2179-3963","authenticated-orcid":false,"given":"Tamer","family":"Hellou","sequence":"additional","affiliation":[{"name":"Mayo Clinic"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amie","family":"Fonder","sequence":"additional","affiliation":[{"name":"Mayo Clinic"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miriam","family":"Hobbs","sequence":"additional","affiliation":[{"name":"Mayo Clinic"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9195-1589","authenticated-orcid":false,"given":"Nadine","family":"Abdallah","sequence":"additional","affiliation":[{"name":"Mayo clinic"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1556-6416","authenticated-orcid":false,"given":"Yi","family":"Lin","sequence":"additional","affiliation":[{"name":"Mayo Clinic"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4640-7311","authenticated-orcid":false,"given":"Mustaqeem","family":"Siddiqui","sequence":"additional","affiliation":[{"name":"Mayo Clinic"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"KYLE","sequence":"additional","affiliation":[{"name":"Mayo Clinic"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7011-0286","authenticated-orcid":false,"given":"Martin","family":"Kort\u00fcm","sequence":"additional","affiliation":[{"name":"University Hospital of W\u00fcrzburg"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7680-0819","authenticated-orcid":false,"given":"Hermann","family":"Einsele","sequence":"additional","affiliation":[{"name":"University Hospital W\u00fcrzburg"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5862-1833","authenticated-orcid":false,"given":"S. Vincent","family":"Rajkumar","sequence":"additional","affiliation":[{"name":"Mayo Clinic"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5392-9284","authenticated-orcid":false,"given":"Shaji","family":"Kumar","sequence":"additional","affiliation":[{"name":"Mayo clinic"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3853-5196","authenticated-orcid":false,"given":"Morie","family":"Gertz","sequence":"additional","affiliation":[{"name":"Mayo Clinic"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"issue":"6","key":"ref1","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1038\/leu.2010.60","article-title":"Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management","volume":"24","author":"Kyle RA","year":"2010","unstructured":"Kyle RA, Durie BG, Rajkumar SV, Landgren O, Blade J, Merlini G, et al. Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management. Leukemia. 2010;24(6):1121\u20137.","journal-title":"Leukemia"},{"issue":"1","key":"ref2","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1038\/s41408-024-01201-9","article-title":"The significance of free light-chain ratio in light-chain monoclonal gammopathy of undetermined significance: a flow cytometry sub-study of the iStopMM screening study","volume":"14","author":"\u00d3skarsson J\u00de","year":"2024","unstructured":"\u00d3skarsson J\u00de, R\u00f6gnvaldsson S, Thorsteinsdottir S, Long TE, \u00d3lafsson A, Eythorsson E, et al. The significance of free light-chain ratio in light-chain monoclonal gammopathy of undetermined significance: a flow cytometry sub-study of the iStopMM screening study. Blood Cancer Journal. 2024;14(1):221.","journal-title":"Blood Cancer Journal"},{"issue":"11","key":"ref3","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1002\/ajh.23827","article-title":"Immunoglobulin light chain amyloidosis is diagnosed late in patients with preexisting plasma cell dyscrasias","volume":"89","author":"Kourelis TV","year":"2014","unstructured":"Kourelis TV, Kumar SK, Go RS, Kapoor P, Kyle RA, Buadi FK, et al. Immunoglobulin light chain amyloidosis is diagnosed late in patients with preexisting plasma cell dyscrasias. Am J Hematol. 2014;89(11):1051\u20134.","journal-title":"Am J Hematol"},{"issue":"12","key":"ref4","doi-asserted-by":"crossref","DOI":"10.3390\/jcm14124146","article-title":"Screening for Systemic Light-Chain Amyloidosis in Patients Over 60 with \u03bb Monoclonal Gammopathies","volume":"14","author":"Zhou P","year":"2025","unstructured":"Zhou P, Mansukhani MM, Yeh R, Lu J, Xia H, Koganti L, et al. Screening for Systemic Light-Chain Amyloidosis in Patients Over 60 with \u03bb Monoclonal Gammopathies. J Clin Med. 2025;14(12).","journal-title":"J Clin Med"},{"issue":"25","key":"ref5","doi-asserted-by":"crossref","first-page":"2699","DOI":"10.1200\/JCO.2013.50.0892","article-title":"Increased Serum Free Light Chains Precede the Presentation of Immunoglobulin Light Chain Amyloidosis","volume":"32","author":"Weiss BM","year":"2014","unstructured":"Weiss BM, Hebreo J, Cordaro DV, Roschewski MJ, Baker TP, Abbott KC, et al. Increased Serum Free Light Chains Precede the Presentation of Immunoglobulin Light Chain Amyloidosis. Journal of Clinical Oncology. 2014;32(25):2699\u2013704.","journal-title":"Journal of Clinical Oncology"},{"issue":"4","key":"ref6","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/j.beha.2007.08.001","article-title":"Epidemiology of the plasma-cell disorders","volume":"20","author":"Kyle RA","year":"2007","unstructured":"Kyle RA, Rajkumar SV. Epidemiology of the plasma-cell disorders. Best Pract Res Clin Haematol. 2007;20(4):637\u201364.","journal-title":"Best Pract Res Clin Haematol"},{"issue":"1","key":"ref7","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/s00277-010-1028-8","article-title":"Asymptomatic immunoglobulin light chain amyloidosis (AL) at the time of diagnostic bone marrow biopsy in newly diagnosed patients with multiple myeloma and smoldering myeloma. A series of 144 cases and a review of the literature","volume":"90","author":"Siragusa S","year":"2011","unstructured":"Siragusa S, Morice W, Gertz MA, Kyle RA, Greipp PR, Lust JA, et al. Asymptomatic immunoglobulin light chain amyloidosis (AL) at the time of diagnostic bone marrow biopsy in newly diagnosed patients with multiple myeloma and smoldering myeloma. A series of 144 cases and a review of the literature. Ann Hematol. 2011;90(1):101\u20136.","journal-title":"Ann Hematol"},{"issue":"34","key":"ref8","doi-asserted-by":"crossref","first-page":"4319","DOI":"10.1200\/JCO.2013.50.8499","article-title":"Coexistent multiple myeloma or increased bone marrow plasma cells define equally high-risk populations in patients with immunoglobulin light chain amyloidosis","volume":"31","author":"Kourelis TV","year":"2013","unstructured":"Kourelis TV, Kumar SK, Gertz MA, Lacy MQ, Buadi FK, Hayman SR, et al. Coexistent multiple myeloma or increased bone marrow plasma cells define equally high-risk populations in patients with immunoglobulin light chain amyloidosis. J Clin Oncol. 2013;31(34):4319\u201324.","journal-title":"J Clin Oncol"},{"key":"ref9","author":"Madan S","year":"2010","unstructured":"Madan S, Dispenzieri A, Lacy MQ, Buadi F, Hayman SR, Zeldenrust SR, et al. Clinical features and treatment response of light chain (AL) amyloidosis diagnosed in patients with previous diagnosis of multiple myeloma. Mayo Clin Proc. 2010;85(3):232-8."},{"issue":"4","key":"ref10","doi-asserted-by":"crossref","first-page":"731","DOI":"10.3390\/hemato3040049","article-title":"IgM-Related Immunoglobulin Light Chain (AL) Amyloidosis","volume":"3","author":"Sarosiek S","year":"2022","unstructured":"Sarosiek S, Branagan AR, Treon SP, Castillo JJ. IgM-Related Immunoglobulin Light Chain (AL) Amyloidosis. Hemato. 2022;3(4):731\u201341.","journal-title":"Hemato"},{"issue":"3\u20134","key":"ref11","doi-asserted-by":"crossref","first-page":"315","DOI":"10.3109\/10428199709059685","article-title":"Incidence and impact of light chain associated (AL) amyloidosis on the prognosis of patients with multiple myeloma treated with autologous transplantation","volume":"27","author":"Desikan KR","year":"1997","unstructured":"Desikan KR, Dhodapkar MV, Hough A, Waldron T, Jagannath S, Siegel D, et al. Incidence and impact of light chain associated (AL) amyloidosis on the prognosis of patients with multiple myeloma treated with autologous transplantation. Leuk Lymphoma. 1997;27(3\u20134):315\u20139.","journal-title":"Leuk Lymphoma"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.2147\/CMAR.S287922","article-title":"Effects of Amyloid Light-Chain Amyloidosis on Clinical Characteristics and Prognosis in Multiple Myeloma: A Single-Center Retrospective Study","volume":"13","author":"Xu J","year":"2021","unstructured":"Xu J, Wang M, Shen Y, Yan M, Xie W, Wang B, et al. Effects of Amyloid Light-Chain Amyloidosis on Clinical Characteristics and Prognosis in Multiple Myeloma: A Single-Center Retrospective Study. Cancer Manag Res. 2021;13:1343\u201356.","journal-title":"Cancer Manag Res"},{"issue":"6","key":"ref13","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.3324\/haematol.2022.282264","article-title":"Light chain amyloidosis associated with Waldenstr\u00f6m macroglobulinemia: treatment and survival outcomes","volume":"108","author":"Gustine JN","year":"2023","unstructured":"Gustine JN, Szalat RE, Staron A, Joshi T, Mendelson L, Sloan JM, et al. Light chain amyloidosis associated with Waldenstr\u00f6m macroglobulinemia: treatment and survival outcomes. Haematologica. 2023;108(6):1680\u20134.","journal-title":"Haematologica"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1038\/s41375-018-0286-7","article-title":"Primary systemic amyloidosis in patients with Waldenstr\u00f6m macroglobulinemia","volume":"33","author":"Zanwar S","year":"2019","unstructured":"Zanwar S, Abeykoon J, Ansell S. Primary systemic amyloidosis in patients with Waldenstr\u00f6m macroglobulinemia. Leukemia. 2019;33:790\u20134.","journal-title":"Leukemia"},{"issue":"5","key":"ref15","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1038\/s41375-019-0667-6","article-title":"IgM AL amyloidosis: delineating disease biology and outcomes with clinical, genomic and bone marrow morphological features","volume":"34","author":"Sidana S","year":"2020","unstructured":"Sidana S, Larson DP, Greipp PT, He R, McPhail ED, Dispenzieri A, et al. IgM AL amyloidosis: delineating disease biology and outcomes with clinical, genomic and bone marrow morphological features. Leukemia. 2020;34(5):1373\u201382.","journal-title":"Leukemia"},{"issue":"5","key":"ref16","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1002\/ajh.23400","article-title":"Immunoglobulin light chain amyloidosis: 2013 update on diagnosis, prognosis, and treatment","volume":"88","author":"Gertz MA","year":"2013","unstructured":"Gertz MA. Immunoglobulin light chain amyloidosis: 2013 update on diagnosis, prognosis, and treatment. American journal of hematology. 2013;88(5):416\u201325.","journal-title":"American journal of hematology"},{"issue":"4","key":"ref17","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1080\/13506129.2020.1778461","article-title":"Presence of t(11;14) in AL amyloidosis as a marker of response when treated with a bortezomib-based regimen","volume":"27","author":"Dumas B","year":"2020","unstructured":"Dumas B, Yameen H, Sarosiek S, Sloan JM, Sanchorawala V. Presence of t(11;14) in AL amyloidosis as a marker of response when treated with a bortezomib-based regimen. Amyloid. 2020;27(4):244\u20139.","journal-title":"Amyloid"},{"issue":"7","key":"ref18","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1038\/leu.2016.369","article-title":"Interphase fluorescence in situ hybridization in untreated AL amyloidosis has an independent prognostic impact by abnormality type and treatment category","volume":"31","author":"Muchtar E","year":"2017","unstructured":"Muchtar E, Dispenzieri A, Kumar SK, Ketterling RP, Dingli D, Lacy MQ, et al. Interphase fluorescence in situ hybridization in untreated AL amyloidosis has an independent prognostic impact by abnormality type and treatment category. Leukemia. 2017;31(7):1562\u20139.","journal-title":"Leukemia"},{"issue":"22","key":"ref19","doi-asserted-by":"crossref","first-page":"5814","DOI":"10.1182\/bloodadvances.2025017214","article-title":"Prospective real-world evaluation of t(11;14) prevalence and disease biology in multiple myeloma: MEDICI study analysis","volume":"9","author":"Spencer A","year":"2025","unstructured":"Spencer A, Gavriatopoulou M, Coriu D, Lys\u00e9n A, Guti\u00e9rrez NC, Escalante F, et al. Prospective real-world evaluation of t(11;14) prevalence and disease biology in multiple myeloma: MEDICI study analysis. Blood Adv. 2025;9(22):5814\u201327.","journal-title":"Blood Adv"},{"issue":"1","key":"ref20","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1038\/s41408-023-00807-9","article-title":"Multiple myeloma with t(11;14): impact of novel agents on outcome","volume":"13","author":"Puertas B","year":"2023","unstructured":"Puertas B, Gonz\u00e1lez-Calle V, Sobejano-Fuertes E, Escalante F, Rey-Bua B, Padilla I, et al. Multiple myeloma with t(11;14): impact of novel agents on outcome. Blood Cancer J. 2023;13(1):40.","journal-title":"Blood Cancer J"},{"issue":"6","key":"ref21","first-page":"1874","article-title":"t(11;14) status is stable between diagnosis and relapse and concordant between detection methodologies based on fluorescence in situ hybridization and next-generation sequencing in patients with multiple myeloma","volume":"109","author":"Avet-Loiseau H","year":"2024","unstructured":"Avet-Loiseau H, Thi\u00e9baut-Millot R, Li X, Ross JA, Hader C. t(11;14) status is stable between diagnosis and relapse and concordant between detection methodologies based on fluorescence in situ hybridization and next-generation sequencing in patients with multiple myeloma. Haematologica. 2024;109(6):1874\u201381.","journal-title":"Haematologica"},{"issue":"12","key":"ref22","doi-asserted-by":"crossref","first-page":"e538-48","DOI":"10.1016\/S1470-2045(14)70442-5","article-title":"International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma","volume":"15","author":"Rajkumar SV","year":"2014","unstructured":"Rajkumar SV, Dimopoulos MA, Palumbo A, Blade J, Merlini G, Mateos MV, et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014;15(12):e538-48.","journal-title":"Lancet Oncol"},{"issue":"1","key":"ref23","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1080\/13506129.2022.2093635","article-title":"Guidelines for non-transplant chemotherapy for treatment of systemic AL amyloidosis: EHA-ISA working group","volume":"30","author":"Wechalekar AD","year":"2023","unstructured":"Wechalekar AD, Cibeira MT, Gibbs SD, Jaccard A, Kumar S, Merlini G, et al. Guidelines for non-transplant chemotherapy for treatment of systemic AL amyloidosis: EHA-ISA working group. Amyloid. 2023;30(1):3\u201317.","journal-title":"Amyloid"},{"key":"ref24","author":"Gertz MA","year":"2005","unstructured":"Gertz MA, Comenzo R, Falk RH, Fermand JP, Hazenberg BP, Hawkins PN, et al. Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): A consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis. American Journal of Hematology. 2005;79(4):319\u2009\u2013\u200928."},{"issue":"10","key":"ref25","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1038\/s41408-020-00366-3","article-title":"International Myeloma Working Group risk stratification model for smoldering multiple myeloma (SMM)","volume":"10","author":"Mateos M-V","year":"2020","unstructured":"Mateos M-V, Kumar S, Dimopoulos MA, Gonz\u00e1lez-Calle V, Kastritis E, Hajek R, et al. International Myeloma Working Group risk stratification model for smoldering multiple myeloma (SMM). Blood Cancer Journal. 2020;10(10):102.","journal-title":"Blood Cancer Journal"},{"issue":"18","key":"ref26","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1056\/NEJMoa2409029","article-title":"Daratumumab or Active Monitoring for High-Risk Smoldering Multiple Myeloma","volume":"392","author":"Dimopoulos MA","year":"2025","unstructured":"Dimopoulos MA, Voorhees PM, Schjesvold F, Cohen YC, Hungria V, Sandhu I, et al. Daratumumab or Active Monitoring for High-Risk Smoldering Multiple Myeloma. N Engl J Med. 2025;392(18):1777\u201388.","journal-title":"N Engl J Med"},{"key":"ref27","author":"Morgan G","year":"2024","unstructured":"Morgan G, Nau AN, Wong S, Spencer BH, Shen Y, Hua A, et al. An updated AL-Base reveals ranked enrichment of immunoglobulin light chain variable genes in AL amyloidosis. bioRxiv. 2024."},{"issue":"8","key":"ref28","doi-asserted-by":"crossref","first-page":"4953","DOI":"10.1074\/jbc.M114.615401","article-title":"Differential Effects on Light Chain Amyloid Formation Depend on Mutations and Type of Glycosaminoglycans *","volume":"290","author":"Blancas-Mej\u00eda LM","year":"2015","unstructured":"Blancas-Mej\u00eda LM, Hammernik J, Marin-Argany M, Ramirez-Alvarado M. Differential Effects on Light Chain Amyloid Formation Depend on Mutations and Type of Glycosaminoglycans *. Journal of Biological Chemistry. 2015;290(8):4953\u201365.","journal-title":"Journal of Biological Chemistry"},{"issue":"1","key":"ref29","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/s12915-022-01506-w","article-title":"Widespread amyloidogenicity potential of multiple myeloma patient-derived immunoglobulin light chains","volume":"21","author":"Sternke-Hoffmann R","year":"2023","unstructured":"Sternke-Hoffmann R, Pauly T, Norrild RK, Hansen J, Tucholski F, H\u00f8ie MH, et al. Widespread amyloidogenicity potential of multiple myeloma patient-derived immunoglobulin light chains. BMC Biol. 2023;21(1):21.","journal-title":"BMC Biol"},{"issue":"1","key":"ref30","doi-asserted-by":"crossref","first-page":"13785","DOI":"10.1038\/s41598-021-93019-9","article-title":"Exploring the sequence features determining amyloidosis in human antibody light chains","volume":"11","author":"Rawat P","year":"2021","unstructured":"Rawat P, Prabakaran R, Kumar S, Gromiha MM. Exploring the sequence features determining amyloidosis in human antibody light chains. Sci Rep. 2021;11(1):13785.","journal-title":"Sci Rep"},{"issue":"7","key":"ref31","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1182\/bloodadvances.2018016782","article-title":"Light chain type predicts organ involvement and survival in AL amyloidosis patients receiving stem cell transplantation","volume":"2","author":"Sidiqi MH","year":"2018","unstructured":"Sidiqi MH, Aljama MA, Muchtar E, Buadi FK, Warsame R, Lacy MQ, et al. Light chain type predicts organ involvement and survival in AL amyloidosis patients receiving stem cell transplantation. Blood Advances. 2018;2(7):769\u201376.","journal-title":"Blood Advances"}],"container-title":[],"original-title":[],"link":[{"URL":"https:\/\/www.researchsquare.com\/article\/rs-9227260\/v1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.researchsquare.com\/article\/rs-9227260\/v1.html","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T09:00:14Z","timestamp":1776762014000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.researchsquare.com\/article\/rs-9227260\/v1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,8]]},"references-count":31,"URL":"https:\/\/doi.org\/10.21203\/rs.3.rs-9227260\/v1","relation":{},"subject":[],"published":{"date-parts":[[2026,4,8]]},"subtype":"preprint"}}